Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Innoviva stock | $10.41

Own Innoviva stock in just a few minutes.

Fact checked

Innoviva, Inc is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Innoviva employs 5 staff and has a trailing 12-month revenue of around USD$322.3 million.

How to buy shares in Innoviva

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Innoviva. Find the stock by name or ticker symbol: INVA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Innoviva reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$10.41, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Innoviva, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Innoviva. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Innoviva share price

Use our graph to track the performance of INVA stocks over time.

Innoviva shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$10.41
52-week rangeUSD$7.58 - USD$15.62
50-day moving average USD$11.0326
200-day moving average USD$11.9859
Wall St. target priceUSD$10
PE ratio 6.4709
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.907

Buy Innoviva shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Innoviva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innoviva price performance over time

Historical closes compared with the close of $10.41 from 2020-12-09

1 week (2021-01-14) -19.11%
1 month (2020-12-24) -15.64%
3 months (2020-10-23) 1.76%
6 months (2020-07-23) -23.29%
1 year (2020-01-23) -27.56%
2 years (2019-01-23) -47.13%
3 years (2018-01-23) 15.68
5 years (2016-01-22) 4.41%

Is Innoviva under- or over-valued?

Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innoviva's P/E ratio

Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Innoviva shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Innoviva's PEG ratio

Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Innoviva's EBITDA

Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$310 million.

The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.

Innoviva financials

Revenue TTM USD$322.3 million
Operating margin TTM 96.18%
Gross profit TTM USD$261 million
Return on assets TTM 24.24%
Return on equity TTM 67.59%
Profit margin 67.16%
Book value $4.789
Market capitalisation USD$1.3 billion

TTM: trailing 12 months

Shorting Innoviva shares

There are currently 9.4 million Innoviva shares held short by investors – that's known as Innoviva's "short interest". This figure is 1.8% down from 9.5 million last month.

There are a few different ways that this level of interest in shorting Innoviva shares can be evaluated.

Innoviva's "short interest ratio" (SIR)

Innoviva's "short interest ratio" (SIR) is the quantity of Innoviva shares currently shorted divided by the average quantity of Innoviva shares traded daily (recently around 697582.414307). Innoviva's SIR currently stands at 13.42. In other words for every 100,000 Innoviva shares traded daily on the market, roughly 13420 shares are currently held short.

However Innoviva's short interest can also be evaluated against the total number of Innoviva shares, or, against the total number of tradable Innoviva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innoviva's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Innoviva shares in existence, roughly 90 shares are currently held short) or 0.1624% of the tradable shares (for every 100,000 tradable Innoviva shares, roughly 162 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Innoviva.

Find out more about how you can short Innoviva stock.

Innoviva share dividends

We're not expecting Innoviva to pay a dividend over the next 12 months.

Have Innoviva's shares ever split?

Innoviva's shares were split on a 1241:1000 basis on 3 June 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.

Innoviva share price volatility

Over the last 12 months, Innoviva's shares have ranged in value from as little as $7.58 up to $15.62. A popular way to gauge a stock's volatility is its "beta".

INVA.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.5633. This would suggest that Innoviva's shares are less volatile than average (for this exchange).

Innoviva overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site